14 results about "Viral nonstructural protein" patented technology

The invention discloses a variable region amino acid sequence of a monoclonal antibody of a West Nile virus non-structural protein NS1 and application of the variable region amino acid sequence, and belongs to the technical field of medicines. According to the invention, West Nile virus non-structural protein NS1 expressed by human embryo kidney 293 cells is used as an antigen to immunize a rabbit, B cells capable of being specifically combined with the West Nile virus non-structural protein NS1 are screened from rabbit spleen cells through flow sorting, and a signal peptide and a variable region gene fragment of an antibody are cloned through reverse transcription-polymerase chain reaction; according to the present invention, the non-structural protein NS1 of flaviviridae flaviviridae virus is taken as a template, and is connected with a constant region gene to an expression vector, and after mammalian cell expression and purification, the monoclonal antibody which has high affinity and is not combined with the non-structural protein NS1 of other eight viruses of flaviviridae flaviviridae virus is obtained through enzyme-linked immunosorbent assay; the monoclonal antibody has application value in diagnosis and prevention and treatment of West Nile virus infection.

The present invention relates to the field of pharmacological research, and specifically relates to a compound as shown in general formula (I), or a pharmaceutically acceptable salt, tautomer, enantiomer, diastereomer, racemate, hydrate, ester, solvate, metabolic precursor or prodrug thereof, a preparation method therefor, a pharmaceutical combination comprising same, and a use of the compound in the prevention and / or treatment of respiratory diseases caused by viruses (such as SARS-CoV2, SARS-CoV, and MERS-CoV) and in the inhibition of nonstructural proteins of the related viruses, such as a papain-like protease protein.

The invention relates to an application of SLC15A3 in preparation of an anti-dengue virus drug, and discovers that a novel antiviral protein SLC15A3 has a novel application of efficiently targeting a dengue virus non-structural protein NS4A so as to inhibit the proliferation of a dengue virus in a host cell. The invention develops a new field of clinical application of the humanized antiviral protein in the field of antiviral prevention and treatment, so that a new thought and direction are provided for drug development of targeted dengue virus non-structural protein NS4A, a scientific basis is provided for development of anti-dengue virus drugs, and a new thought is provided for clinical antiviral treatment.

The invention provides preparation and application of an adenovirus non-structural protein, and aims at a novel chimpanzee adenovirus to screen the non-structural protein capable of detecting the titer of the chimpanzee adenovirus with high sensitivity and strong specificity. Immunofluorescence detection is carried out on the virus titer through the antibody prepared from the non-structural protein, the result is close to the detection result of a fluorescence counting method of flow cytometry, compared with detection of hypervariable region protein antibodies and whole virus antibodies in existing structural protein, the accuracy and sensitivity of detection are remarkably improved, very high specificity can be kept, and the method is suitable for large-scale popularization and application. Therefore, the chimpanzee adenovirus titer can be detected more simply, conveniently and efficiently.

The invention relates to a novel anti-dengue virus (DENV) monoclonal antibody, a preparation method of the antibody, and related application of the antibody in immunodetection. The anti-DENV monoclonal antibody is targeted to a non-structural protein 1 (NS1) of DENV, and shows high sensitivity and high specificity of targeted DENV NS1 protein, so that the clinical detection requirements of DENV can be met.

The invention relates to the technical field of antibodies, in particular to a 3D protein monoclonal antibody and application thereof. The monoclonal antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises the following three complementary determining regions CDR: CDR1 shown as SEQ ID No.5, CDR2 shown as SEQ ID No.6, and CDR3 shown as SEQ ID No.7; the heavy chain variable region comprises the following three complementary determining regions: CDR1 shown as SEQ ID No.5, CDR2 shown as SEQ ID No.6, and CDR3 shown as SEQ ID No.7; the light chain variable region comprises the following three complementary determining regions CDR: CDR1 as shown in SEQ ID No.8, CDR2 with the sequence of WAS, and CDR3 as shown in SEQ ID No.9. The light chain variable region has the advantages that the light chain variable region can be used for preparing the light chain variable region; the invention provides a specific monoclonal antibody of a foot and mouth disease virus non-structural protein 3D protein. A Western blotting test shows that the specific monoclonal antibody specifically reacts with the non-structural protein 3D; indirect immunofluorescence tests show that the antibody has good reactivity with an FMDV O-type strain.

The invention discloses a variable region amino acid sequence of a monoclonal antibody of a West Nile virus non-structural protein NS1 and application of the variable region amino acid sequence, and belongs to the technical field of medicines. According to the invention, West Nile virus non-structural protein NS1 expressed by human embryo kidney 293 cells is used as an antigen to immunize a rabbit, B cells capable of being specifically combined with the West Nile virus non-structural protein NS1 are screened from rabbit spleen cells through flow sorting, and a signal peptide and a variable region gene fragment of an antibody are cloned through reverse transcription-polymerase chain reaction; according to the present invention, the non-structural protein NS1 of flaviviridae flaviviridae virus is taken as a template, and is connected with a constant region gene to an expression vector, and after mammalian cell expression and purification, the monoclonal antibody which has high affinity and is not combined with the non-structural protein NS1 of other eight viruses of flaviviridae flaviviridae virus is obtained through enzyme-linked immunosorbent assay; the monoclonal antibody has application value in diagnosis and prevention and treatment of West Nile virus infection.

The present disclosure relates to polypeptides that specifically bind to Dengue virus non-structural protein 1, including antibodies and fragments thereof. The antibody or antigen-binding fragment thereof may specifically bind Dengue virus (DENV) serotype 4 and include: a heavy chain variable region that comprises at least one CDR amino acid sequence selected from the group consisting of: SGYNWH, YIHYSGGTNYNPSLKS, RTGTVPFAY, SYVMH, YLNPYNDDTKYNEKFKG, and GPPYALDY. The present disclosure further relates to methods of producing the polypeptides of the present disclosure, methods of diagnosing DENV, and methods of treating a DENV infection.

This invention provides an optimized method for enhancing self-amplifying RNA expression and an enhanced self-amplifying RNA. Specifically, it provides an optimized method for enhancing self-amplifying RNA expression, which involves codon optimization. The optimized region is a specific region of the alphavirus non-structural protein sequence of the self-amplifying RNA, where the alphavirus non-structural protein is nsP1234. It also provides a method for preparing the enhanced self-amplifying RNA, an enhanced self-amplifying RNA, and a plasmid. This application improves the expression efficiency of the self-amplifying RNA target gene by designing and constructing codon sequence optimization for certain regions of these non-structural proteins.

Provided is the preparation of a Zika virus non-structural protein NS2A polypeptide and its antibody. A polypeptide is provided, which comprises the amino acid sequence shown in SEQ ID NO.1 or a variant thereof, and the variant has 90% sequence identity with the amino acid sequence shown in SEQ ID NO.1. The present invention for the first time provides a ZIKV NS2A polypeptide and a polypeptide antibody. After the polypeptide is coupled with KLH, a ZIKV NS2A antibody is prepared, and the antibody can be used in Western blot, immunofluorescence experiments and other antigen-antibody recognition experiments.

The invention provides an optimization method for enhancing self-amplification RNA (Ribonucleic Acid) expression and enhanced self-amplification RNA, and particularly provides the optimization method for enhancing self-amplification RNA expression, the optimization is codon optimization, a codon optimization region is an alphavirus non-structural protein sequence specific region of the self-amplification RNA, alphavirus non-structural protein is nsP1234, and the alphavirus non-structural protein is nsP1234. The invention also provides a preparation method of the enhanced self-amplification RNA, the enhanced self-amplification RNA and a plasmid. According to the invention, the codon sequences of partial regions of the non-structural proteins are optimized through design and construction, so that the expression efficiency of the self-amplification RNA target gene is improved.

This invention relates to the field of biotechnology, specifically to a monoclonal antibody against the non-structural protein V of peste des petits ruminants (PPR) virus and its gene sequence. The invention discloses a monoclonal antibody 3E10 against PPR non-structural protein V, wherein the sequence of monoclonal antibody 3E10 includes the heavy chain variable region shown in SEQ ID NO.7 and the light chain variable region shown in SEQ ID NO.8. Monoclonal antibody 3E10 specifically reacts with PPR and exhibits high affinity, enabling its detection of PPR. This provides new material for functional studies of PPR V protein and the development of diagnostic reagents, and offers new technical support for the successful implementation of the global PPR elimination program.

The invention discloses a variable region amino acid sequence of a monoclonal antibody of a West Nile virus non-structural protein NS1 and application of the variable region amino acid sequence, and belongs to the technical field of medicines. According to the invention, West Nile virus non-structural protein NS1 expressed by human embryo kidney 293 cells is used as an antigen to immunize a rabbit, B cells capable of being specifically combined with the West Nile virus non-structural protein NS1 are screened from rabbit spleen cells through flow sorting, and a signal peptide and a variable region gene fragment of an antibody are cloned through reverse transcription-polymerase chain reaction; according to the present invention, the non-structural protein NS1 of flaviviridae flaviviridae virus is taken as a template, and is connected with a constant region gene to an expression vector, and after mammalian cell expression and purification, the monoclonal antibody which has high affinity and is not combined with the non-structural protein NS1 of other eight viruses of flaviviridae flaviviridae virus is obtained through enzyme-linked immunosorbent assay; the monoclonal antibody has application value in diagnosis and prevention and treatment of West Nile virus infection.

The invention discloses a recombinant plasmid based on a Getah virus replicon, a vesicle vaccine, a preparation method and an application, and belongs to the technical field of bioengineering. The method comprises the following steps: by taking codon-optimized Getah virus non-structural protein as a skeleton, introducing a reporter gene eGEP-T2A-VSVG, and constructing a pGETV-eGFP-VSVG recombinant plasmid; further synthesizing a rabies virus RABVG protein, and replacing the VSVG protein with the rabies virus RABVG protein to construct a pGETV-eGFP-RABVG recombinant plasmid. The two obtained recombinant plasmids capable of stably passing can stably express a large amount of VSVG protein and RABVG protein under the action of a Geitai virus replication subsystem and a subgene promoter and the assistance of T2A, infectious and self-replicating VSVG virus-like vesicles and RABVG virus-like vesicles are formed, and the recombinant plasmids can be used for preparing novel vesicle vaccines and can be used for preparing VSVG virus-like vesicles and RABVG virus-like vesicles. The important technical support is provided for the prevention and control of the rabies virus.